在 Kotak 将其上调至“买入”后，Emcure Pharmaceuticals 的股价飙升，理由是尽管存在风险，但仍保持强劲增长。 Emcure Pharmaceuticals' stock surged after Kotak upgraded it to "Buy," citing strong growth despite risks.

在 Kotak Institutional Equities 将其评级上调至“买入”评级后，Emcure Pharmaceuticals 的股价上涨了近 10%，预计 1,680 卢比可能上涨 20.68%。 Emcure Pharmaceuticals' stock rose nearly 10% after Kotak Institutional Equities upgraded it to a "Buy" rating, predicting a potential 20.68% upside to Rs 1,680. Kotak指出强劲增长、健康利润和良好的财务管理是积极因素,但指出风险包括药品定价案件和诉讼。 Kotak cited strong growth, healthy margins, and good financial management as positives, but noted risks including drug price-fixing cases and litigation. 经纪公司预计今后几年销售和收入将强劲增长,特别是在加拿大这样的国际市场。 The brokerage expects robust sales and earnings growth over the next few years, especially in international markets like Canada.